Financials in GBp. Standardized financial statements.
A compact view of how E-therapeutics Plc turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £318,000 | £475,000 | £477,000 | £317,000 | £456,000 | £44,000 | £0 | £0 | £0 | £0 |
| Revenue Growth? | -33.1% | -0.4% | +50.5% | -30.5% | +936.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | £0 | £0 | £0 | £0 | £0 | £0 | £62,000 | £56,000 | £73,000 | £0 |
| Gross Profit? | £318,000 | £475,000 | £477,000 | £317,000 | £456,000 | £44,000 | -£62,000 | -£56,000 | -£73,000 | £0 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | £14.11M | £10.25M | £9.83M | £4.69M | £3.25M | £5.16M | £6.77M | £16.33M | £11.55M | £10.18M |
| Operating Income? | -£13.79M | -£10.24M | -£9.54M | -£4.46M | -£2.88M | -£5.11M | -£6.77M | -£12.97M | -£11.55M | -£10.18M |
| EBITDA? | -£13.72M | -£9.77M | -£9.35M | -£4.37M | -£2.79M | -£5.04M | -£6.70M | -£12.92M | -£11.48M | -£10.10M |
| Income Before Tax | -£13.08M | -£9.77M | -£9.52M | -£4.47M | -£2.87M | -£5.08M | -£6.72M | -£16.20M | -£11.28M | -£9.82M |
| Income Tax Expense | -£1.92M | -£1.50M | -£1.45M | -£784,000 | -£526,000 | -£1.09M | -£1.36M | -£3.07M | -£2.46M | -£2.04M |
| Net Income? | -£11.17M | -£8.27M | -£8.07M | -£3.68M | -£2.35M | -£4.00M | -£5.36M | -£13.13M | -£8.82M | -£7.78M |
| EPS? | £-0.02 | £-0.02 | £-0.02 | £-0.01 | £-0.01 | £-0.01 | £-0.02 | £-0.05 | £-0.03 | £-0.03 |
| Diluted EPS? | £-0.02 | £-0.02 | £-0.02 | £-0.01 | £-0.01 | £-0.01 | £-0.02 | £-0.05 | £-0.03 | £-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality